Aceto Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 137.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 104.83 Cr
as on 23-10-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 662.56%
(FY 2023)
- Profit 11800.43%
(FY 2023)
- Ebitda 341.91%
(FY 2023)
- Net Worth -3.43%
(FY 2023)
- Total Assets -2.76%
(FY 2023)
About Aceto Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 137.00 Cr and a paid-up capital of Rs 104.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aceto Pharma (India) Private Limited India is Madhaviben Dave as COMPANY SECRETARY. Varun Rao, Sunil Punjabi, James Steele, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232GJ2007FTC142338
- Company No.
167356
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
29 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aceto Pharma (India)?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Punjabi  | Managing Director | 07-Feb-2022 | Current |
| Madhaviben Dave | Company Secretary | 11-Oct-2021 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Rao  | Director | 02-Nov-2020 | Current |
| James Steele | Director | 26-Apr-2021 | Current |
| Arpit Butala | Director | 16-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Aceto Pharma (India).
Aceto Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 662.56% increase. The company also saw a substantial improvement in profitability, with a 11800.43% increase in profit. The company's net worth dipped by a decrease of 3.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aceto Pharma (India)?
In 2023, Aceto Pharma (India) had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aceto Pharma (India)?
Unlock and access historical data on people associated with Aceto Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aceto Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aceto Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
